Autopsy report · NCT04903041

A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).

“Unavailable funding”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 8 months after it had already started.
• Suspended: paused, and may or may not restart.
• 300,000 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Sponsor

Jaime Marino

Sponsor type

Industry

Conditions

Cardiovascular Diseases

Participants

300,000 (planned, not actual)

Sites

6

Countries

India

Trials that died the same way

• PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
  “Funding unavailable” (98% match in meaning)
• Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
  “Funding has become unavailable” (94% match in meaning)
• Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
  “funding became unavailable” (94% match in meaning)
• Targeting Leukotrienes in Kidney Disease
  “Funding not available” (91% match in meaning)
• Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
  “Funding was not available” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.